Tensegrity Pharma Signs Research Collaboration Agreement with argenx on TSP-101

Tensegrity Pharma, Inc. (Headquarters: Tokyo; CEO: Takahito Nakahara; hereinafter “Tensegrity Pharma”) is pleased to announce the signing of a joint research collaboration and option agreement with argenx BV (hereinafter “argenx”), a global immunology company, regarding TSP-101.
Under this agreement, Tensegrity Pharma and argenx will collaborate closely together on the TSP-101 research and development program, jointly advancing non-clinical studies, clinical trials, and related development activities. Through this collaboration, the companies aim to validate the scientific value and clinical potential of TSP-101 and pursue hypothesis testing in muscle-wasting diseases as well as a broad range of other inflammatory and immune related conditions.

TSP-101 is our first fully human monoclonal antibody targeting Fn14, designed to control various inflammatory diseases, including cancer cachexia, by inhibiting Fn14 signaling. TSP-101 is also the lead asset in Tensegrity Pharma’s pipeline and is currently under development as a treatment for cancer cachexia, with the support of the AMED (Japan Agency for Medical Research and Development) Strengthening Program for Pharmaceutical Startup Ecosystem (Project title: Development of TSP-101 for cancer cachexia). argenx brings extensive knowledge and experience in immunology and antibody drug development, and we believe this joint collaboration represents an important step toward accelerating the development of TSP-101.

About Tensegrity Pharma, Inc.
Tensegrity Pharma is a startup company committed to eliminating bottlenecks in the global drug discovery process. We evaluate and reclaim therapeutic candidates that were discontinued for strategic reasons, applying our unique drug discovery perspective. By conducting exploratory clinical development trials on a global scale, we aim to unlock their value and ultimately pursue out-licensing or M&A opportunities with pharmaceutical companies.

Representative : CEO, Takahito Nakahara
Address              : Nihonbashi Mizuno Building 7F, 1-11-12 Nihonbashi Muromachi, Chuo-ku, Tokyo 103-0022
Established       : March 7, 2023
URL                     : https://tensegritypharma.com/

About argenx BV
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.

Representative: CEO, Tim Van Hauwermeiren
Address : Industriepark-Zwijnaarde 7, 9052 Zwijnaarde, Belgium
Established : 2008
URL : https://www.argenx.com/

For inquiries regarding this matter
Tensegrity Pharma, Inc. Public Relations Department
[email protected]